Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue: +93.9%
EPS: −120.0%
Free cash flow: +13.4%
Total debt: +57.4%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

8.51 0.50 +6.24%

Follow IBRX

Alert me

Market cap: $8.5B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 4/9
Altman Z: −10.16
Beneish M: 4.57
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

ImmunityBio, Inc. (IBRX) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022
Product revenue, net	113 99.73%	14 95.96%	0 0.00%	0 0.00%
Other revenues	0 0.27%	1 4.04%	1 100.00%	0 100.00%
Revenue	113	15	1	0

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	113 100.00%	15 100.00%	1 100.00%	0 100.00%
Revenue	113	15	1	0

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡
Operating income	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2017	FY2016	FY2015	FY2014	FY2013
U.S.	113 99.75%	14 96.40%	0 4.98%	0 17.50%	0 39.94%	1 84.79%	2 90.69%	0 100.00%	0 100.00%	0 80.93%	0 57.88%	0 63.33%
Europe	0 0.25%	1 3.60%	1 95.02%	0 82.50%	1 60.06%	0 15.21%	0 9.31%	0 0.00%	0 0.00%	0 8.90%	0 34.32%	0 15.83%
Non-US	—	—	—	—	—	—	—	0 0.00%	0 0.00%	0 10.17%	0 7.80%	0 20.83%
Revenue	113	15	1	0	1	1	2	0	0	0	1	1

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.